When was KD Pharma Group founded?

KD Pharma Group was founded in 1988 and raised its 1st funding round 31 years after it was founded.

Where is KD Pharma Group located?

KD Pharma Group is headquartered in Bioggio, Switzerland.

Who is the current CEO of KD Pharma Group?

Oscar Groet of KD Pharma Group.

How many employees does KD Pharma Group have?

As of Aug 31, 2026, the latest employee count at KD Pharma Group is 340.

Is KD Pharma Group a funded company?

KD Pharma Group is a funded company, having raised a total of $***** in its 1st and only funding round, a Conventional Debt round on Jun 19, 2019.

When was the latest funding round of KD Pharma Group?

KD Pharma Group's latest funding was a $***** Conventional Debt round on Jun 19, 2019, with participation from 1 investor. Its primary sector is Biopharma Outsourcing. Globally, the Biopharma Outsourcing sector has seen $1.29B in funding in 2026 to date.

Where does KD Pharma Group rank among its competitors?

KD Pharma Group ranks 22nd amongst 958 active competitors, of which 38 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Embio, which secured $50M in May, 2026.

Who are the top competitors of KD Pharma Group?

KD Pharma Group's top competitors include Laurus Labs, Symbiotec and NGL Fine Chem. Among them, Embio secured the most recent funding round in May, 2026.

KD Pharma Group - 2026 Company Profile, Team, Funding & Competitors

KD Pharma Group is a funded company based in Bioggio (Switzerland), founded in 1988. It operates as a Provider of Omega 3 API manufacturing services. KD Pharma Group has raised an undisclosed amount in funding. The company has 958 active competitors, including 38 funded and 137 that have exited. Its top competitors include companies like Laurus Labs, Symbiotec and NGL Fine Chem.

Company Details

Website: kdpharmagroup.com
Social
Email ID: *****@kdpharmagroup.com
Phone Number: +41 **********

Key Metrics

Founded Year

1988

Location

Bioggio, Switzerland

Stage

Funding Raised

Latest Funding Round

Conventional Debt, Jun 19, 2019, $*****

Investors

Capiton & 2 more

Ranked

22^nd among 958 active competitors

Employee Count

340 as on Aug 31, 2026

Similar Companies

Laurus Labs & 1222 more

View KD Pharma Group's full profile

KD Pharma Group has raised funding over 1 round. Its latest funding round was a Conventional Debt round on Jun 19, 2019 for $*****. 1 investor participated in its latest round. KD Pharma Group has 3 institutional investors.

Here is the list of recent funding rounds of KD Pharma Group:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 19, 2019	9361986	Conventional Debt	7593691	8058367	8499765	2265709

Access funding benchmarks and valuations. Sign up today!

View details of KD Pharma Group's funding rounds and investors

KD Pharma Group's employee count trend

KD Pharma Group has 340 employees as of Aug 26. Here is KD Pharma Group's employee count trend over the years:

Employee count trend for KD Pharma Group

Uncover KD Pharma Group's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of KD Pharma Group include Laurus Labs, Symbiotec and NGL Fine Chem. Here is the list of Top 10 competitors of KD Pharma Group, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Laurus Labs 2005, Hyderabad (India), Public	Pharmaceutical and biotechnology company	$230M	F-Prime Capital, IKP Knowledge Park & 3 others	78/100
2nd	Symbiotec 2002, Indore (India), Acquired	Manufacturer of non sterile steroid hormone based APIs and intermediates	$61.1M	Franklin Templeton Investments, Actis & 21 others	64/100
3rd	NGL Fine Chem 1981, Mumbai (India), Public	CDMO specializing in multi stage organic synthesis of generic APIs and fine chemicals	-	-	59/100
4th	Neuland 1984, Hyderabad (India), Public	Manufacturer of active pharmaceutical ingredients (APIs) and peptides	-	India Capital Growth, InvAscent & 1 others	58/100
5th	Embio 1986, Mumbai (India), Late Stage	Contract research and manufacturing company engaged in APIs and chiral intermediates	$50.3M	UTI, GURU NARAYAN FINCAP & 26 others	58/100
6th	Snapdragon Chemistry 2014, Cambridge (United States), Acquired	CDMO providing API development, manufacturing, and analytical services	-	Asymchem, C2I Accelerator & 1 others	55/100
7th	SeQuent 2002, Bengaluru (India), Acquired	APIs Manufacturer	-	Nepean Capital, Thecarlylegroup.fr & 2 others	54/100
8th	ST PHARM 2008, Siheung si (South Korea), Public	CDMO providing oligonucleotide, mRNA, and small molecule services	-	E&Investment, Synergy IB investment & 1 others	54/100
9th	Hikal 1988, Mumbai (India), Public	Traditional company offering contract research, custom synthesis & custom manufacturing of APIs and intermediates	-	IFC	53/100
10th	Enaltec Labs 2006, Mumbai (India), Acquired	Provider of complex small-volume technology-driven pharmaceutical products	$8.56M	InvAscent, Medtech Global & 7 others	52/100
22nd	KD Pharma Group 1988, Bioggio (Switzerland), Funding Raised	Provider of Omega 3 API manufacturing services	-	Capiton, Global PE Alliance & 1 others	45/100